Royal Bank Of Canada Aerie Pharmaceuticals Inc Transaction History

Royal Bank Of Canada

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$6.37 - $15.23 $19,912 - $47,608	-3,126 Reduced 31.11%	6,923 $105,000
Q2 2022 Aug 15, 2022	BUY	$4.95 - $9.16 $2,346 - $4,341	474 Added 4.95%	10,049 $75,000
Q1 2022 May 16, 2022	SELL	$5.64 - $9.8 $32,035 - $55,664	-5,680 Reduced 37.23%	9,575 $87,000
Q4 2021 Feb 14, 2022	BUY	$7.02 - $13.33 $86,247 - $163,772	12,286 Added 413.81%	15,255 $106,000
Q3 2021 Nov 15, 2021	BUY	$11.32 - $16.63 $19,277 - $28,320	1,703 Added 134.52%	2,969 $34,000

Q2 2021 Aug 16, 2021	BUY	$15.16 - $18.97 $19,192 - $24,016	1,266 New	1,266 $20,000

2.4M

Ticker AERI
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 49,390,500
Description
Aerie Pharmaceuticals, Inc., a pharmaceutical company, focuses on the discovery, development, and commercialization of ophthalmic therapies for open-angle glaucoma, dry eye, diabetic macular edema, and wet age-related macular degeneration in the United States. Its products include Rhopressa, a once-daily eye drop to reduce elevated intraocular p...

Get notified when there are updates to the investment portfolio of Royal Bank Of Canada, based on Form 13F filings with the SEC.

Stay updated on Royal Bank Of Canada with notifications on news.